Ligand Pharmaceuticals (LGND) Financials

$289.25

$3.65 (1.28%)

As on 10-Sep-2026 16:02EDT

Market cap

$5,694 Mln

Revenue (TTM)

$291 Mln

P/E Ratio

29.8

P/B Ratio

5.9

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	290.54	268.09	167.13	131.31	196.25	241.54
Cost of Revenue	4.12	6.59	11.07	35.05	52.83	62.18
Gross Profit	286.42	261.50	156.06	96.27	143.42	179.37
Operating Expenses	185.49	214.30	178.67	84.32	140.38	75.52
Operating Profit (EBIT)	100.93	47.20	-22.61	11.94	3.04	103.85
Other Income	--	--	--	--	--	-11.97
Profit before Tax	237.96	158.96	2.52	63.66	36.01	72.21
Provision for Tax	40.74	34.51	6.55	9.84	41.23	-4.15
Profit after Tax (Net Income)	197.22	124.45	-4.03	52.15	-33.36	57.14
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-33.36	57.59

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	967.52	1,017.21	830.44	700.91	597.49	821.16
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	1,171.62	505.98	74.22	69.52	66.37	434.77
Current Liabilities	46.74	37.45	37.11	16.78	98.81	41.67
Total Liabilities	2,232.61	1,560.64	941.77	787.22	762.67	1,297.59

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	728.76	728.37	610.22	549.79	499.07	832.84
Current Assets	1,457.12	832.27	331.56	237.43	263.60	464.75
Total Assets	2,232.61	1,560.64	941.77	787.22	762.67	1,297.59
Total Debt*	1,131.45	451.49	7.11	6.17	87.75	324.39
Net Current Assets	1,410.38	794.82	294.45	220.65	164.79	423.09

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	49.36	97.05	49.58	137.85	78.80
Cash Flow from Investing Activities	--	-377.32	-143.66	-11.68	163.62	30.52
Cash from Financing Activities	--	428.22	97.14	-59.95	-275.99	-137.76
Net Cash Inflow / Outflow	--	--	--	--	--	-28.44

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	9.48	5.89	-0.21	2.95	-1.98	3.41
Cash EPS ($)	--	7.49	1.64	5.09	0.05	6.23
Adjusted Book Value ($)	--	48.12	43.77	39.65	35.38	49.07
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	2.34	5.11	2.80	8.16	4.71
Free Cash Flow per Share ($)	--	2.31	4.08	-0.24	7.10	4.19

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	10.79	-0.52	7.49	-3.64	4.94
ROE (%)	19.87	13.47	-0.53	8.03	-4.70	7.47
ROA (%)	12.15	9.95	-0.47	6.73	-3.24	4.30
EBIT Margin (%)	82.50	59.29	3.32	48.98	19.27	38.02
Net Margin (%)	67.88	46.42	-2.41	39.72	-17.00	24.89
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	54.89	0.60	0.27	-0.33	-0.19	0.48
EBIT Growth (%)	396.48	2,761.57	-91.36	70.10	-58.82	219.87
Net Profit Growth (%)	359.97	3,186.63	-107.73	256.33	-158.39	2,014.17
EPS Growth (%)	337.28	28.71	-1.07	2.49	-1.58	20.09
Book Value Growth (%)	6.56	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	29.84	32.11	-504.23	24.21	-33.82	29.19
Price / Book Value	5.92	3.93	2.45	1.80	1.89	2.03
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	19.79	19.27	43.73	10.89	12.37	11.56
Close Price ($)	316.09	189.07	107.15	71.42	66.80	62.18
High Price ($)	320.99	212.49	129.90	85.70	83.95	88.46
Low Price ($)	111.72	93.58	67.53	49.24	29.21	39.70
Market Cap ($ Cr)	5,693.61	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	1.16	0.44	0.01	0.01	0.15	0.40
Short term debt to equity ratio	0.00	0.00	0.00	0.00	0.13	0.00
Current Ratio	31.18	22.23	8.93	14.15	2.67	11.15
Quick Ratio	30.96	21.98	8.55	12.72	2.53	10.50
Interest Coverage	39.44	33.71	1.83	98.04	21.02	4.68

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	24.07	22.77	25.40	29.94	17.85	37.94
Asset Turnover	0.18	0.21	0.19	0.17	0.19	0.18
Receivable days	--	70.50	89.34	103.40	117.89	113.95
Inventory Days	--	644.28	628.04	194.16	140.42	158.06
Payable days	--	234.84	126.32	40.30	47.40	35.80
Cash Conversion Cycle	--	479.94	591.06	257.26	210.92	236.21

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.